Skip Navigation


JAC Advance Access originally published online on January 24, 2008
Journal of Antimicrobial Chemotherapy 2008 61(4):835-837; doi:10.1093/jac/dkn011
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/4/835    most recent
dkn011v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lacroix, C.
Right arrow Articles by de Chauvin, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lacroix, C.
Right arrow Articles by de Chauvin, M. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

In vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against Scytalidium dimidiatum and Scytalidium hyalinum clinical isolates

Claire Lacroix* and Martine Feuilhade de Chauvin

Laboratoire de Mycologie-Parasitologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France

Received 19 July 2007; returned 20 October 2007; revised 13 December 2007; accepted 4 January 2008

* Corresponding author. Tel: +33-1-42-49-95-21; Fax: +33-1-42-49-48-03; E-mail: claire.lacroix{at}sls.aphp.fr

Objectives: The objective of this work was to evaluate the in vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against clinical isolates of Scytalidium dimidiatum and Scytalidium hyalinum.

Methods: Microdilution testing was performed in accordance with the CLSI M38-A method on 17 S. dimidiatum and 15 S. hyalinum clinical isolates.

Results: The MIC ranges of voriconazole, posaconazole, itraconazole, terbinafine, caspofungin and amphotericin B were <0.03 to 0.5 mg/L, 0.06–2 mg/L, <0.03 to >16 mg/L, 0.06–2 mg/L, 0.06–8 mg/L and 0.06–1 mg/L, respectively.

Conclusions: Amphotericin B and voriconazole exhibit the lowest MICs for Scytalidium spp. Voriconazole could be a promising agent for the treatment of these refractory infections.

Keywords: scytalidiosis , dermatomycosis , onychomycosis , antifungal agents , triazoles


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
H. Elinav, U. Izhar, S. Benenson, D. Admon, C. Hidalgo-Grass, I. Polacheck, and M. Korem
Invasive Scytalidium dimidiatum Infection in an Immunocompetent Adult
J. Clin. Microbiol., April 1, 2009; 47(4): 1259 - 1263.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.